A Review of Fluid Biomarkers for Alzheimer’s Disease: Moving from CSF to Blood

被引：212
作者：
Blennow K. [1 ,2 ]
机构：
[1] Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at University of Gothenburg, Mölndal
[2] Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal
来源：
Neurology and Therapy | 2017年 / 6卷 / Suppl 1期
关键词：
Alzheimer’s disease; Biomarkers; Cerebrospinal fluid; Neurofilament light; Neurogranin; Tau protein; β-Amyloid;
D O I：
10.1007/s40120-017-0073-9
中图分类号：
学科分类号：
摘要：
A set of core cerebrospinal fluid (CSF) biomarkers for Alzheimer’s disease (AD) includes total tau (T-tau), phosphorylated tau (P-tau) and β-amyloid 42 (Aβ42). These biomarkers reflect some of the key aspects of AD pathophysiology, including neuronal degeneration, tau phosphorylation with tangle formation, and Aβ aggregation with deposition of the peptide into plaques. The core AD CSF biomarkers have been validated clinically in numerous studies, and found to have a very high diagnostic performance to identify AD, both in the dementia and in the mild cognitive impairment stages of the disease. CSF Aβ42 has also been found to show very high concordance with amyloid PET to identify brain amyloid deposition. The synaptic protein neurogranin is a novel candidate CSF biomarker for AD and prodromal AD. High CSF neurogranin predicts future cognitive decline and seems to be more specific for AD than, for example, T-tau. Importantly, technical developments have given ultrasensitive measurement techniques that allow measurement of brain-specific proteins such as tau and neurofilament light (NFL) in blood samples. Both plasma tau and NFL are increased in AD, and a recent study showed that plasma NFL has a diagnostic performance comparable to the core AD CSF biomarkers, and predicted future cognitive decline. Future large longitudinal clinical studies are warranted to determine the potential for plasma tau and NFL to serve as first-in-line screening tools for neurodegeneration in primary care. © 2017, The Author(s).
引用
收藏
页码：15 / 24
页数：9
相关论文
共 60 条
[11]  
Leinenbach A., Pannee J., Dulffer T., Huber A., Bittner T., Andreasson U., Et al., Mass spectrometry-based candidate reference measurement procedure for quantification of amyloid-beta in cerebrospinal fluid, Clin Chem, 60, 7, pp. 987-994, (2014)
[12]  
Kuhlmann J., Andreasson U., Pannee J., Bjerke M., Portelius E., Leinenbach A., CSF Abeta1-42—an excellent but complicated Alzheimer’s biomarker: a route to standardisation, Clin Chim Acta, 467, pp. 27-33, (2017)
[13]  
Bittner T., Zetterberg H., Teunissen C.E., Ostlund R.E., Militello M., Andreasson U., Et al., Technical performance of a novel, fully automated electrochemiluminescence immunoassay for the quantitation of beta-amyloid (1–42) in human cerebrospinal fluid, Alzheimers Dement., 12, 5, pp. 517-526, (2016)
[14]  
Andreasen N., Minthon L., Vanmechelen E., Vanderstichele H., Davidsson P., Winblad B., Et al., Cerebrospinal fluid tau and Abeta42 as predictors of development of Alzheimer’s disease in patients with mild cognitive impairment, Neurosci Lett, 273, 1, pp. 5-8, (1999)
[15]  
Hansson O., Zetterberg H., Buchhave P., Londos E., Blennow K., Minthon L., Association between CSF biomarkers and incipient Alzheimer’s disease in patients with mild cognitive impairment: a follow-up study, Lancet Neurol., 5, 3, pp. 228-234, (2006)
[16]  
Visser P.J., Verhey F., Knol D.L., Scheltens P., Wahlund L.O., Freund-Levi Y., Et al., Prevalence and prognostic value of CSF markers of Alzheimer’s disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study, Lancet Neurol., 8, 7, pp. 619-627, (2009)
[17]  
Mattsson N., Zetterberg H., Hansson O., Andreasen N., Parnetti L., Jonsson M., Et al., CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment, JAMA J Am Med Assoc, 302, 4, pp. 385-393, (2009)
[18]  
May P.C., Willis B.A., Lowe S.L., Dean R.A., Monk S.A., Cocke P.J., Et al., The potent BACE1 inhibitor LY2886721 elicits robust central Abeta pharmacodynamic responses in mice, dogs, and humans, J Neurosci, 35, 3, pp. 1199-1210, (2015)
[19]  
Sevigny J., Chiao P., Bussiere T., Weinreb P.H., Williams L., Maier M., Et al., The antibody aducanumab reduces Abeta plaques in Alzheimer’s disease, Nature, 537, 7618, pp. 50-56, (2016)
[20]  
Hampel H., Frank R., Broich K., Teipel S.J., Katz R.G., Hardy J., Et al., Biomarkers for Alzheimer’s disease: academic, industry and regulatory perspectives, Nat Rev Drug Discov, 9, 7, pp. 560-574, (2010)
123456